Literature DB >> 10356136

Infantile encephalopathy associated with the MELAS A3243G mutation.

C M Sue1, C Bruno, A L Andreu, A Cargan, J R Mendell, C Y Tsao, M Luquette, J Paolicchi, S Shanske, S DiMauro, D C De Vivo.   

Abstract

MELAS syndrome is typically characterized by normal early development and childhood-onset recurrent neurologic deficits (stroke-like episodes), seizures, short stature, lactic acidosis, and ragged red fibers on muscle biopsy specimens. It is usually, but not invariably, associated with the A3243G point mutation in the mitochondrial DNA tRNALeu(UUR) gene. We report 3 unrelated children with the A3243G mutation who presented with severe psychomotor delay in early infancy. One patient's clinical picture was more consistent with Leigh syndrome, with apneic episodes, ataxia, and bilateral striatal lesions on brain magnetic resonance imaging (MRI). The second patient had generalized seizures refractory to treatment and bilateral occipital lesions on brain MRI. The third child had atypical retinal pigmentary changes, seizures, areflexia, and cerebral atrophy on brain MRI. All patients had several atypical features in addition to early onset: absence of an acute or focal neurologic deficit, variable serum and cerebrospinal fluid lactate levels, lack of ragged red fibers in muscle biopsy specimens. The proportion of mutant mtDNA in available tissues was relatively low (range, 5% to 51% in muscle; 4% to 39% in blood). These observations further extend the phenotypic expression of the A3243G "MELAS" mutation. Our findings confirm previous observations that there is poor correlation between abundance of mutant mtDNA in peripheral tissues and neurologic phenotype. This suggests that other factors contribute to the phenotypic expression of this mutation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10356136     DOI: 10.1016/s0022-3476(99)70283-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  8 in total

Review 1.  Integrating mitochondriomics in children's environmental health.

Authors:  Kelly J Brunst; Andrea A Baccarelli; Rosalind J Wright
Journal:  J Appl Toxicol       Date:  2015-06-05       Impact factor: 3.446

Review 2.  Mitochondrial disease in childhood: mtDNA encoded.

Authors:  Russell P Saneto; Margret M Sedensky
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

Review 3.  Current strategies towards therapeutic manipulation of mtDNA heteroplasmy.

Authors:  Claudia V Pereira; Carlos T Moraes
Journal:  Front Biosci (Landmark Ed)       Date:  2017-01-01

Review 4.  Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis.

Authors:  D A Rossignol; R E Frye
Journal:  Mol Psychiatry       Date:  2011-01-25       Impact factor: 15.992

Review 5.  Evidence of Mitochondrial Dysfunction in Autism: Biochemical Links, Genetic-Based Associations, and Non-Energy-Related Mechanisms.

Authors:  Keren K Griffiths; Richard J Levy
Journal:  Oxid Med Cell Longev       Date:  2017-05-29       Impact factor: 6.543

6.  Clinical and molecular characterization of mitochondrial DNA disorders in a group of Argentinian pediatric patients.

Authors:  Mariana Amina Loos; Gimena Gomez; Lía Mayorga; Roberto Horacio Caraballo; Hernán Diego Eiroa; María Gabriela Obregon; Carlos Rugilo; Fabiana Lubieniecki; Ana Lía Taratuto; María Saccoliti; Cristina Noemi Alonso; Hilda Verónica Aráoz
Journal:  Mol Genet Metab Rep       Date:  2021-02-25

Review 7.  The molecular pathology of pathogenic mitochondrial tRNA variants.

Authors:  Uwe Richter; Robert McFarland; Robert W Taylor; Sarah J Pickett
Journal:  FEBS Lett       Date:  2021-02-12       Impact factor: 3.864

8.  Mitochondrial Genomics: A complex field now coming of age.

Authors:  Elizabeth M McCormick; Colleen C Muraresku; Marni J Falk
Journal:  Curr Genet Med Rep       Date:  2018-05-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.